? MOLECULAR CARCINOGENESIS AND CHEMOPREVENTION (MCC) The Molecular Carcinogenesis and Chemoprevention (MCC) Program at The Ohio State University Comprehensive Cancer Center (OSUCCC), led by Steven Clinton, MD, PhD, and Richard Fishel, PhD, has 48 members from 22 Departments and 8 OSU Colleges (Arts and Sciences, Dentistry, Education and Human Ecology, Food, Agriculture and Environmental Science, Medicine, Pharmacy, Public Health, and Veterinary Medicine). The MCC Program examines cancer as an integrated and dynamic process over time, with a major focus on the interface between genetics and the environment that collectively impacts the carcinogenesis cascade. This approach provides a foundation for chemoprevention and dietary interventions to reduce the burden of cancer in high-risk individuals as well as to decrease the incidence, mortality and morbidity of cancer in our Ohio catchment area (CA) and the nation. Our expertise extends to defining standards for genetic screening and counselling as well defining dietary and nutritional guidelines that impact cancer risk through public policy, nationally and globally.
The Specific Aims of the MCC Program are: 1) Carcinogenesis: To characterize the genetic, molecular and cellular changes induced by germline, chemical, physical, hormonal or microbiological mediators that contribute to neoplastic transformation and multistage carcinogenesis; 2) Chemoprevention: To develop and characterize novel cancer chemopreventive agents and define their efficacy, safety, and mechanisms of action using biochemical, cellular and preclinical models that ultimately lead to early phase human studies; and, 3) Diet, Nutrition and Metabolism: To identify dietary patterns, nutritional components, and lifestyle variables that enhance or inhibit the carcinogenesis cascade across the continuum of cancer progression. MCC Program members published 547 cancer-relevant manuscripts between 12/01/14 and 11/30/19. Of these, 14% were intra- programmatic (multiple authors from MCC Program), 31% were inter-programmatic (authors from multiple OSUCCC Programs), and 72% were multi-institutional (authors from both CC and another institution). The total collaborative publications is 83%. MCC Program funding stands at $7.9M in overall direct, cancer-focused funding, of which $7.0M is peer-reviewed, including $6.8M direct funding from NIH ($3.4M from NCI). Over the last five years, MCC Program members have accrued 1,487 participants to trials; 670 to interventional trials and 817 to non-interventional trials. MCC members serve as leaders of the Ohio Colorectal Cancer Prevention Initiative involving 3,651 participants (3,310 colorectal and 341 endometrial) and ORIEN Total Cancer Care with enrollment of 50,683.The MCC program is fully integrated with the high priority crosscutting research initiatives of the OSUCCC and future plans complement and enhance programmatic aims while promoting interactions with the other research Programs and focus on 1) metabolic signatures in carcinogenesis and prevention; 2) the microbiome and immunology interface with Pelotonia Institute for Immuno-Oncology initiatives; and 3) collaborative efforts with the Center for Cancer Engineering.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Pan, Pan; Huang, Yi-Wen; Oshima, Kiyoko et al. (2018) An immunological perspective for preventing cancer with berries. J Berry Res 8:163-175

Showing the most recent 10 out of 2602 publications